Transdifferentiation of Pancreatic Duct Cells Into Beta-Like Cells
AssigneeJoslin Diabetes Center, Inc.
InventorPeng Yi
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods of inducing insulin production from pancreatic duct cells in response to glucose or transdifferentiating pancreatic duct cells into insulin-producing beta-like cells by administering an agent that inhibits aldehyde dehydrogenase family 3 member B2 (ALDH3B2) protein or an agent that inhibits the expression of ALDH3B2 gene. This disclosure also relates to methods of treatment of diabetes by administering an agent that inhibits ALDH3B2 protein or an agent that inhibits the expression of ALDH3B2 gene.
Claims26
A method of inducing insulin production from pancreatic duct cells in response to glucose comprising administering an agent that inhibits ALDH3B2 protein or an agent that inhibits the expression of ALDH3B2 gene.
A method of transdifferentiating pancreatic duct cells into insulin-producing beta-like cells comprising administering an agent that inhibits ALDH3B2 protein or an agent that inhibits the expression of ALDH3B2 gene.
-7. (canceled)
A method of treating a subject with diabetes comprising administering an agent that inhibits ALDH3B2 protein or an agent that inhibits the expression of ALDH3B2 gene, wherein the agent increases insulin secretion from the pancreas.
(canceled)
(canceled)
-16. (canceled)
A method of preventing the development of diabetes comprising:
- a. screening a subject for risk factors for developing diabetes;
- b. determining if the subject has increased risk of developing diabetes;
- and
- c. administering an agent that inhibits ALDH3B2 protein or an agent that inhibits the expression of ALDH3B2 gene to a subject that has an increased risk of diabetes.
(canceled)
(canceled)
Dependencies are inferred from the claim text.